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Abstract 
Benzodiazepine-related aggression is understudied in the literature, in particular little 
is known about the motivational factors which may contribute to the development of this 
paradoxical response. The revised Reinforcement Sensitivity Theory provides a theoretical 
framework from which to understand the relevant underlying motivational processes. The 
current study aimed to identify the role of approach and avoidance motivational tendencies in 
the occurrence of benzodiazepine-related aggression. Data regarding benzodiazepine and 
other substance use, approach and avoidance motivation, and general and physical aggressive 
behaviour were collected via self-report questionnaires. Participants were a convenience 
sample (n = 204) who reported using benzodiazepines in the previous year. Participants were 
primarily male (62.7%), aged 18-51 years old. Hierarchical multiple regressions indicated 
that general and physical aggression were predicted by alprazolam use and Drive, a facet of 
approach motivation. Overall, lower diazepam use significantly predicted higher levels of 
general aggression. However, when diazepam-preferring participants were examined in 
isolation of the larger sample (23.5% of sample), problematic (dependent) diazepam use was 
associated with greater aggression scores, as was dependence risk for alprazolam-preferring 
participants (39.7% of sample). The findings highlight the importance of motivational factors 
and benzodiazepine use patterns in understanding benzodiazepine-related aggression, with 
implications for violent offender rehabilitation.  
 
Keywords: benzodiazepines, aggressive behaviour, Reinforcement Sensitivity Theory 
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Motivational drive and alprazolam use: A recipe for aggression? 
1.0 Introduction 
Benzodiazepines are commonly used to manage anxiety or agitated behaviour 
(Ashton, 2002). However, for an estimated 1-20% of users, benzodiazepine use is followed 
by an aggressive response (Lader, 2011). The somewhat paradoxical nature of this response, 
coupled with the high medical, financial and personal costs associated with aggressive 
behaviour, suggests that changes to prescribing policies and regulatory strategies may be 
required to reduce the likelihood of benzodiazepine-related aggression from occurring.  
However, surprisingly little attention has been paid to understanding the psychological 
processes associated with benzodiazepine-related aggression. Controlled laboratory studies 
have demonstrated that alprazolam and diazepam use can result in an increased aggressive 
response in some participants (e.g., Bond and Silveira, 1993; Bond et al., 1995; Ben-Porath 
and Taylor, 2002; Wallace and Taylor, 2009), and animal studies report the possible 
influence of concurrent alcohol use (de Almeida et al., 2010) and pre-existing aggressive 
tendencies (Ferrari et al., 1997; Weerts et al., 2010) in benzodiazepine-related aggression. 
Yet, few human studies have examined potential contributory factors (i.e., dose, other 
substance use, psychological or intrapersonal factors, situation; see Albrecht et al., 2014, for 
systematic review). Of note, irrespective of a long-standing proposal that intrapersonal 
factors are important in understanding this response (Lion et al., 1975; Hoaken and Stewart, 
2003), only a handful of studies have investigated the role of various personality 
characteristics in benzodiazepine-related aggression (i.e., trait anxiety, hostility; Wilkinson, 
1985; Cherek et al., 1990; Ben-Porath and Taylor, 2002; Dåderman et al., 2002). This limited 
research, and the absence of a clear theoretical framework with which to explore 
benzodiazepine-related aggression impacts on our ability to develop meaningful, and testable, 
hypotheses and intervention strategies. We argue that current models of approach and 
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avoidance motivational tendencies may be able to inform our understanding of 
benzodiazepine-related aggression.  
Motivational systems are theorised to underlie a number of human behaviours, 
including violent and aggressive behaviour. Gray’s (1982) Reinforcement Sensitivity Theory 
and its recent revision (rRST; Gray and McNaughton, 2003) purports to explain behavioural 
output and emotional expression based on three separate but interacting motivational systems. 
The behavioural approach system (BAS) promotes movement towards incentives and 
rewards, often involving goal-directed behaviour and impulsive action. The fight-flight-
freeze system (FFFS) promotes fearful avoidance of a threat, and over-activation clinically 
presents as phobia or panic (Corr and Perkins, 2006). The behavioural inhibition system 
(BIS) promotes risk assessment and conflict resolution (Corr, 2008), and is stimulated by 
simultaneous and similar activation of the other two systems (Pickering and Corr, 2008). As 
demonstrated by prior research, the independent and interactive effects of these motivational 
systems have informed our understanding of aggressive behaviour. It is therefore expected 
that the application of this theory to benzodiazepine-related aggression will provide 
meaningful insight into the response, on which intervention strategies could be based. 
Aggression appears to involve a strong approach motivational component (i.e., BAS 
mediated action such as antagonism; Smits and Kuppens, 2005). That is, aggression may in 
part be the result of high levels of motivated action towards goals or rewards. Indeed, studies 
with university students have reported that high levels of BAS are associated with anger and 
aggressive behaviour (Harmon-Jones, 2003; Harmon-Jones and Peterson, 2008). However, 
theoretical understanding of approach motivation (BAS) suggests that it involves multiple 
aspects, including behavioural restraint, planning and goal-directed behaviour (Segarra et al., 
2014), and the use of a broad, unidimensional measure of BAS in the above studies fails to 
account for such complexity. Instead, greater specificity is afforded through the use of a 
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multidimensional measure of approach motivation. The BIS/BAS scales (Carver and White, 
1994) were designed to account for the dynamic and multifaceted nature of the BAS.  
Empirical evidence suggests that Drive is the most important facet of BAS in our 
understanding of aggressive behaviour (e.g., Seibert et al., 2010). Drive (BAS-Dr) involves 
persistent goal pursuit and functional impulsivity; whilst Fun Seeking involves dysfunctional 
impulsivity, with minimal thought to consequences; and Reward Responsiveness involves 
positive energy and affect in response to reward cues (Tull et al., 2010).  BAS-Dr has been 
positively associated with the experience of anger (Harmon-Jones, 2003; Smits and Kuppens, 
2005; Cooper et al., 2008), anger arousal, displaced aggression, the tendency to not suppress 
angry feelings or prevent the expression of anger (Cooper et al., 2008), self-reported physical 
aggression (Harmon-Jones, 2003), relational aggression (Miller et al., 2012), and laboratory 
proxies of aggressive behaviour (Seibert et al., 2010).  In addition, Beaver and colleagues 
(2008) identified that with increasing BAS-Dr, neural structures and dopaminergic pathways 
are activated in a similar pattern to that observed in relation to both reward processing and 
aggression, providing some explanation as to why BAS-Dr is so important in understanding 
aggression. Further conceptual understanding of the link between BAS-Dr and aggressive 
behaviour is afforded through the concept of frustrative non-reward, which is experienced 
when the expected reward is higher than the actual reward (Corr, 2002). Indeed, although 
predominantly associated with the experience of positive affect (i.e., through goal 
attainment), BAS-Dr has also been associated with the experience of negative affect, 
especially sadness, frustration and anger, experienced in the context of blocked or challenged 
reward attainment (Carver, 2004). Such scenarios may influence an aggressive response. 
Following such theorising, aggression may be especially likely if the individual also 
experiences sensitivity to cues of punishment or threat (i.e., avoidance motivational 
tendencies). Essentially, aggressive behaviour may involve a facilitative interplay between 
DRIVE, ALPRAZOLAM & AGGRESSION  6 
 
appetitive and aversive motivational systems, where aggression is more likely when an 
individual with high BAS-Dr also experiences strong avoidance tendencies.  
Such an interaction may be especially important in the understanding of 
benzodiazepine-related aggression. Evidence suggests that benzodiazepines selectively 
interfere with the conflict resolution system (BIS) by making approach behaviour more likely 
(Pickering and Corr, 2008). As part of its conflict resolution role, the BIS mediates cautious 
approach behaviour when it is considered necessary to approach a threat (Perkins et al., 
2007). In an individual with strong approach motivation tendencies (i.e., BAS-Dr), BIS may 
become increasingly activated in the context of threat or frustration compared to FFFS (i.e., 
goal frustrations/threats may be more likely to be considered necessary to approach rather 
than avoid in order to attain the goal). When coupled with benzodiazepine use, which further 
disinhibits the BIS from promoting risk averse avoidance behaviour, aggressive behaviour 
may result. Indeed, BIS has been associated with reactive aggression (Miller et al., 2012), 
potentially reflecting the frustration response, and at extremely high levels of BIS activation, 
the related emotional disturbance may increase aggression risk (Hatfield and Dula, 2014). As 
yet no studies have attempted to explore these specific hypotheses in substance-related 
aggression, particularly benzodiazepine-related aggression. Such investigation of the rRST 
motivational systems and their interactive effects will provide further insight into this 
relationship, with implications for violent offender rehabilitation and the continued 
prescription of benzodiazepines.    
1.1 The current study 
The current study aims to test the hypothesis that BAS-Dr plays a role in predicting 
benzodiazepine-related aggression, but that the interaction between BAS-Dr and BIS 
accounts for greater variance. Due to their prevalent use within the sample, the current study 
will explicitly focus on diazepam and alprazolam in relation to both general aggressive 
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behaviour (i.e., anger, hostility, verbal aggression) and specifically physical aggression. Data 
regarding the participants’ substance use, mental health, and criminal history, and recent 
psychological functioning will also be gathered. It is predicted that: 
1. BAS-Dr, or the tendency to persistently pursue appetitive goals, will significantly predict 
benzodiazepine-related general and physical aggression.  
2. BAS-Dr will moderate the relationship between BIS and aggressive outcomes.  
Specifically, it is predicted that the relationship between BIS and benzodiazepine-related 
aggressive behaviour will be stronger for individuals with high levels of BAS-Dr. 
2.0 Method 
2.1 Design and procedure  
Participants were recruited via a purposeful sampling method, which utilised an 
online electronic questionnaire and paper based questionnaires located at health services. 
Online participants were recruited through electronic platforms (Facebook, Reddit), 
newspaper adverts, and paper flyers posted around the host university. Health service clients 
were recruited from a community based outpatient alcohol and drug treatment service and a 
residential alcohol and drug treatment facility via flyers  or conversation with their treating 
clinician. Consent was implied by completion of the questionnaire and all survey responses 
were anonymous. After completing the questionnaire, participants were invited to enter a 
separate draw for one of six $50.00 shopping vouchers and to provide feedback about the 
survey.  The raffle was drawn at the completion of data collection. Inclusion criteria were age 
of 18 years or older and use of benzodiazepines in the past 12 months (whether prescribed or 
non-prescribed). There were no additional exclusion criteria. The study was approved by the 
relevant ethics committees.  
2.2 Materials  
2.2.1 Demographics 
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Demographic questions included current prescription medication, treatment history 
for drug, alcohol, and mental health issues, and history of substance-related or violent charges 
or convictions. A brief measure of recent psychological functioning (Depression, Anxiety and 
Stress Scales [DASS-21]; Lovibond and Lovibond, 1995) was also included. 
2.2.2 Substance and benzodiazepine use 
A modified version of the Alcohol, Smoking and Substance Involvement Screening 
Test (ASSIST), an eight-item questionnaire designed to detect psychoactive substance use 
and related problems (WHO ASSIST Working Group [WHO], 2002), was used to assess 
lifetime substance involvement and benzodiazepine-related dependency and harms. The 
majority of the items were altered to refer only to the benzodiazepine the respondent selected 
as their preferred type for non-medically prescribed use. Non-medically prescribed use 
(NMP) was defined as using benzodiazepines not prescribed by their doctor or when taken 
more frequently or at higher doses than their doctor prescribed. Taking benzodiazepines for 
NMP reasons may include to feel better, get high, have fun, or to substitute a usual drug of 
choice. By separating medically-prescribed and NMP use, we were able to isolate data 
regarding the misuse of benzodiazepines, and specifically explore aggressive responses 
following such use. We focussed on non-medically prescribed use in order to further our 
understanding of the sequelae of benzodiazepine use which may not be readily observed or 
monitored by prescribers or other health professionals (e.g., due to the frequent diversion of 
benzodiazepines onto the black market; Best et al., 2013). Additional items regarding 
benzodiazepine and substance use patterns were developed through consultation with 
academics and clinicians within the alcohol and other drugs field, specifically regarding item 
wording, relevance and exhaustiveness. Respondents were instructed to select the most 
appropriate answer/s or provide brief written responses.  
2.2.3 BIS/BAS  
DRIVE, ALPRAZOLAM & AGGRESSION  9 
 
The Behavioural Inhibition System and Behavioural Activation System Scales 
(BIS/BAS; Carver and White, 1994) is a 24-item self-report questionnaire designed to assess 
Gray’s (1982) reward and punishment sensitivities. Items are rated on a 4-point Likert scale 
(1 = strongly agree, 4 = strongly disagree), with four filler items. A five factor model was 
used to reflect the revised theory; the three BAS factors, BIS, and FFFS (Heym et al., 2008). 
In the current study, moderate to high internal consistency was demonstrated for each 
subscale (α = 0.67 - 0.82).  
2.2.4 Aggression  
The Aggression Questionnaire (AQ; Buss and Perry, 1992) is a 29-item self-report 
questionnaire which measures physical aggression, verbal aggression, anger, and hostility. 
Items are rated on a 5-point Likert scale (1 = extremely uncharacteristic of me, 5 = extremely 
characteristic of me), and a total aggression score can be calculated by summing all subscale 
scores. The instructions were altered to prompt participants to respond to the questionnaire in 
relation to the last time they had used benzodiazepines for NMP reasons, on an occasion 
when they were not consuming other drugs or alcohol. Internal consistency for the current 
study was high for the total score (α = 0.95) and across all factors (α = 0.84-0.88).  
2.3 Statistical analyses 
Where possible, parametric analyses were conducted, and means, standard deviations, 
and 95% confidence intervals (CI) are reported. Non-parametric chi-square tests of 
independence are used where assumptions are violated and with categorical variables. 
Hierarchical multiple regressions were used to investigate the primary research questions.  
2.3.1 Model specification and invariance testing 
Model specification was purely conceptual, and based on understandings of the 
aggression and rRST literature. Therefore, age, gender, previous drug and alcohol use, and 
prior violent convictions were statistically controlled. However, due to the use of two 
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recruitment methods, it was necessary to determine whether the data could be pooled without 
deleterious effects on the main analyses. As determined through exploration of the larger 
sample, the internet and health centre recruitment subsamples differed on a number of 
demographic variables. Therefore, invariance analyses using the Chow test (DeMaris, 2004) 
were conducted, at the p < 0.05 standard. Based on the outcome of these tests, the prediction 
of both general aggression (∆χ2 (15) = 9310.373, p < 0.05) and physical aggression (∆χ2 (15) 
= 1368.56, p < 0.05) varied according to whether the data was pooled or separated by 
recruitment source.  However, due to the size of the health centre subsample relevant for the 
aggression analyses (i.e., NMP use with AQ scores; n = 30), it is likely that the lack of power 
in the health centre subsample may have artificially led to a significant difference from the 
pooled sample model. The planned model on such a small subsample would likely inflate the 
chance of Type 2 error, due to the lack of statistical power available. An a priori G*Power 
(version 3.1.9.2) analysis indicated that a sample of 160 participants was required to run the 
planned model in order to detect a small effect (0.15) against the p<0.05 criterion. It was 
therefore decided to pool the data and include a sample recruitment variable in the analyses.  
3.0 Results 
3.1 Participant characteristics  
The final sample consisted of 204 adult community members (62.7% male) who 
regularly use benzodiazepines, recruited via the internet (n = 174; 63.2% male) and health 
services (n = 30; 60.0% male), aged between 18 and 51 years old (M = 27.12, SD = 8.21). 
Participant demographic characteristics are displayed in Table 1.  
The sample reported moderate to high scores across the BIS/BAS scales, and 
moderate levels of psychological distress (see Table 2). The sample reported high rates of 
poly-substance use, with the two most commonly used substances in the month prior to 
reporting (other than tobacco) being alcohol and cannabis (see Table 1). Less than a third of 
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the sample admitted previously injecting an illicit substance (n = 61; 29.9%), though almost 
half of these participants had done so in the last three months (n = 27; 44.26%). In the three 
months prior to survey completion, half (54.4%) of the sample reported drinking alcohol on 
at least a weekly basis, whilst 82.4% reported using illicit drugs on at least a weekly basis. Of 
these, the majority reported using one or two types of illicit drugs per week (77.4%), with 
17.9% using three types, and only 4.8% (n = 8) using 4 or more types of illicit drugs per 
week.  
3.1.2 Benzodiazepine profile  
On average, participants began using NMP benzodiazepines at 20.46 years old (SD = 
6.17). NMP benzodiazepines were most frequently acquired through friends (53.4%) or the 
black market (34.3%), and only 13.7% reported to have engaged in doctor shopping. Most 
participants (72.5%) reported using benzodiazepines with other substances; especially alcohol 
(17.6%), cannabis (11.3%), or both (8.3%).  As expected, diazepam and alprazolam were 
most likely to be used for NMP reasons (52.9% and 54.3% respectively; see Table 3), and 
were explicitly preferred for NMP use by 23.5% and 39.7%, respectively.  ASSIST scores 
generally reflected a moderate risk of dependence (see Table 2). Although used relatively 
infrequently over the year prior to survey completion (Table 3), participants consumed 
diazepam and alprazolam at high average doses (see Table 4). Alprazolam was used at the 
highest average doses, and at a level considerably higher than recognised prescribing 
guidelines1 (i.e., up to 33mgs; ‘Alprazolam’, 2013). Diazepam and alprazolam were mostly 
used to reduce anxiety and tension (29.8%, 30.0% respectively) or to get high (14.5%, 24.6% 
respectively), as well as to reduce withdrawal from other substances (11.3%) for diazepam 
and to assist sleep (8.5%) for alprazolam.  
3.2 Main analyses  
                                                          
1
 Prescribing guidelines suggest a daily range of 0.5-4.0mg per day (‘Alprazolam’, 2013). 
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Due to their high rate of misuse in the current sample (52.9-54.3%; see Table 3) 
compared to other benzodiazepines enquired about (9.3-24.6%), the role of diazepam and 
alprazolam were specifically assessed in the main analyses. It is notable that such patterns of 
use aligns with Australian data showing alprazolam and diazepam to be among the most 
widely prescribed (Islam et al., 2014) and misused (Nielsen et al., 2008; Stafford & Burns, 
2012) benzodiazepines, and also the most widely studied in relation to exploring the 
benzodiazepine-aggression link (Albrecht et al., 2014). 
Bivariate correlations between the variables of interest demonstrated that both general 
and physical aggression scores were significantly associated with higher risk of alprazolam 
and diazepam dependence, psychological distress (DASS), BAS-Drive, and having a violent 
conviction (see Table 5). Physical aggression was also positively associated with having a 
substance-related conviction. Increased alprazolam doses were significantly associated, albeit 
at a low strength, with weaker BIS-related anxiety and fear, having a substance-related 
conviction, and a tendency to use multiple other substances when consuming 
benzodiazepines. Higher diazepam doses were associated with having violent and substance-
related convictions. Increased risk of dependence to alprazolam and diazepam was associated 
with increased psychological distress, though alprazolam risk was not associated with DASS-
anxiety.  
3.2.1 Predicting benzodiazepine-related aggression  
Two hierarchical multiple regressions were conducted, to explore whether BIS/BAS 
variables could predict benzodiazepine-related aggression over and above control and 
benzodiazepine variables. In both models, control variables were entered at Step 1, diazepam 
and alprazolam use at Step 2, BIS/BAS main effects at Step 3, and the interaction term at 
Step 4. Two cases were removed for the purposes of the subsequent analyses due to violation 
of regression assumptions. The variables used to compose the interaction term (BAS-Dr, BIS-
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Anx) were centered in order to reduce multicollinearity, and categorical variables included in 
the regression analyses were standardized using dummy-coding.  
3.2.1.1 General aggression. Inclusion of the control variables at Step 1 explained 
5.5% of the variance in general aggression (Fchange (6, 195) = 1.903, p = 0.082). Entry of the 
benzodiazepine variables at Step 2 significantly improved the model, explaining an additional 
3.7% of the variance; Fchange (2, 193) = 3.910, p = 0.022. Entry of the BIS/BAS main effects 
at Step 3 again significantly improved the model, explaining an additional 6.7% of the 
variance; Fchange (5, 188) = 3.009, p = 0.012. The inclusion of the interaction term at Step 4 
did not significantly improve the model (∆R2 = 0.008); Fchange (1, 187) = 1.769, p = 0.185. 
However, the final model, with all the variables in the equation, was significant and 
accounted for 16.7% of the total variance in general aggression; F(14, 187) = 2.682, p = 
0.001. Alprazolam and diazepam use, and BAS-Dr significantly attributed unique variance to 
general aggression, whilst recruitment group and BAS-FS approached significance (see Table 
6).  Inspection of the data indicates that BAS-Dr and alprazolam use made the strongest 
unique contributions to general aggression. Combined, BAS-Dr (5.29%) and alprazolam use 
(4.04%) contributed just under 10.0% towards the explanation of variance in general 
aggression, as calculated from the part correlation coefficients (Pallant, 2007). 
Due to the significant findings pertaining to diazepam and alprazolam, it was explored 
whether general aggression differed according to benzodiazepine dose. Two follow-up 
independent samples t-tests (two-tailed) indicated that levels of general aggression did not 
differ between those using alprazolam within the prescribing range or above (t(116) = -1.054, 
p = 0.294, 95% C.I. = -13.52 to 4.13, Cohen’s d = -0.20), or between those using diazepam 
within the prescribing range or above; t(108) = -0.849, p = 0.398, 95% C.I. = -14.25 to 5.71, 
Cohen’s d = -0.18.  
DRIVE, ALPRAZOLAM & AGGRESSION  14 
 
3.2.1.2 Physical aggression. Inclusion of the control variables at Step 1 explained 
6.4% of the variance in physical aggression. Entry of the benzodiazepine variables at Step 2 
did not significantly improve the model (∆R2 = 0.015); Fchange (2, 193) = 1.542, p = 0.217. 
Entry of the BIS/BAS variables at Step 3 significantly improved the model (∆R2 = 0.057); 
Fchange (5, 188) = 2.459, p = 0.035. The inclusion of the interaction term at Step 4 did not 
significantly improve the model (∆R2 = .000); Fchange (1, 187) = 0.000, p = 0.991. The final 
model accounted for 13.5% of the total variance in physical aggression; F(14, 187) = 2.084, p 
= 0.014. Alprazolam and BAS-Dr significantly attributed unique variance to physical 
aggression, although recruitment group and BAS-FS approached significance (see Table 7). 
BAS-Dr (4.6%) and alprazolam use (1.8%) uniquely contributed a combined 6.4% towards 
the explanation of variance in physical aggression.  
A follow-up independent samples t-test (two-tailed) indicated that levels of physical 
aggression did not differ between those using alprazolam within the prescribing range or 
above (t(116) = -1.658, p = 0.100, 95% C.I. = -5.36 to 0.48, Cohen’s d = -0.31).  
4.0 Discussion 
Benzodiazepine-related aggression is poorly understood. The current study aimed to 
explore the role of approach and avoidance motivational tendencies in benzodiazepine-related 
aggression. It was proposed that BAS-Dr specifically would be important in understanding 
this response, but that the interaction between BAS-Dr and BIS would account for greater 
variance in benzodiazepine-related aggression. The data partially supported these predictions, 
however the moderation effect was not observed.  
4.1 The role of BAS-Dr in benzodiazepine-related aggression 
The tendency to pursue appetitive goals in a persistent manner (BAS-Dr) has been 
consistently associated with aggression and related tendencies (i.e., anger; Cooper et al., 
2008; Seibert et al., 2010; Miller et al., 2012). The current study extends this literature, by 
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hypothesising that BAS-Dr is important in benzodiazepine-related aggression. In support of 
this hypothesis, BAS-Dr was the strongest unique predictor of both general aggression and 
physical aggression, over and above the influence of benzodiazepine type (diazepam and 
alprazolam). Such outcomes align with research indicating the importance of BAS-Dr in the 
prediction of aggressive behaviour compared to other intrapersonal factors (Seibert et al., 
2010), and importantly, support the contention that our understanding of benzodiazepine-
related aggression may be enhanced via recourse to intrapersonal differences (Lion et al., 
1975; Hoaken and Stewart, 2003).  
Individuals with strong BAS-Dr have been described as antagonistic, competitive, and 
willing to work hard to achieve goals, even if at the expense of others (Segarra et al., 2014). 
Such individuals hold high expectations of rewards following goal attainment (Harmon-
Jones, 2003) and their experienced affect is strongly reflective of their perceived progress 
towards their goal (Carver, 2004). For example, in the context of challenged or blocked goal 
attainment, individuals with high BAS-Dr may experience frustration or anger (Carver, 
2004), such as frustrative non-reward (Corr, 2002). Aggressive behaviour then becomes 
increasingly likely, as during frustration, such individuals display reduced impulse control 
(Beaver et al., 2008) and attention to risk or punishment cues (Avila, 2001). Their ability to 
respond appropriately to stressors or frustrations may become further disinhibited in the 
context of benzodiazepine use (Paton, 2002). Indeed, the current data indicate that individuals 
with stronger BAS-Dr tendencies experienced greater anxiety and stress, which may reflect 
difficulty attaining desired outcomes (Carver, 2004), and tended to consume benzodiazepines 
in the context of other substances, which may further impact on their coping or self-
regulation ability. However, the absence of appropriate causal testing limits the conclusions 
drawn from such associations, though the findings do clearly support the role of persistent 
action towards desired goals in benzodiazepine-related aggressive behaviour. As such, 
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prescribers may benefit from exploring patients’ ability to engage in effective impulse control 
and frustration tolerance strategies prior to prescribing benzodiazepines. Clinical 
presentations which involve established dysregulation of approach and avoidance 
motivational systems (such as post-traumatic stress disorder) may also warrant additional 
caution when prescribing benzodiazepines (e.g., Guina et al., 2015). Investigation of the 
benzodiazepine-aggression relationship within such clinical samples is therefore highlighted. 
The findings have implications for the design of rehabilitation interventions for 
individuals who engage in substance-related aggression. The rRST clearly elucidates that 
different motivational tendencies are associated with different neural structures and patterns 
of activation, and therefore differentially impact other intrapersonal characteristics such as 
emotional tendencies and expression, learning processes, and personality (Corr, 2009). 
Specifically, approach motivations are primarily associated with dopaminergic pathways 
(Pickering and Corr, 2008), and increasing BAS-Dr activation has been associated with 
increased activation of the amygdala (emotional processing centre) and dopamine pathways, 
as well as blunted activation of other neural structures, in patterns synonymous with those 
implicated in aggression and reward processing  (Beaver et al., 2008). The implication of 
BAS-Dr in benzodiazepine-related aggression suggests that such substance-related aggression 
is not altogether dissimilar to non-substance-related aggression, with clear ramifications for 
the treatment of individuals who engage in aggression or violence following benzodiazepine 
use. Notably, although benzodiazepine use may increase the likelihood of disinhibition and 
aggression, removal of the associated substance in isolation of interventions targeting the 
underlying motivational factors (and the related emotional and information processing 
factors, such as expectations regarding aggression; Anderson and Bushman, 2002) may be 
unlikely to result in effective desistance from aggressive behaviour. Such a conclusion is 
further suggested by our findings that BAS-Dr attributed more variance to both aggression 
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outcomes than did either benzodiazepine type tested. It is noted that such theorising is made 
in the absence of structural and/or functional imaging data. 
Interestingly, the expected moderation effect between a strong appetitive and strong 
aversive motivational system on benzodiazepine-related aggressive behaviour failed to 
significantly influence either aggression model. Given that our sample displayed only 
moderate levels of aggression, the proposed interactive effect may be more likely in a more 
violent sample, against clearly defined violent incidents. Furthermore, aggression risk may be 
associated with extremely high levels of BIS activation (Hatfield and Dula, 2014), whilst our 
sample displayed only moderately-high BIS activation. The moderating effect may therefore 
only be relevant to investigations of benzodiazepine-related aggression in individuals with 
higher levels or approach and avoidance motivations than those observed in the current 
sample.   
4.2 Role of benzodiazepine type in benzodiazepine-related aggression 
The primary aim of the current study was to explore the role of approach and 
avoidance motivational tendencies in order to better understand benzodiazepine-related 
aggression. This was done with specific consideration of two commonly used 
benzodiazepines, diazepam and alprazolam. Notably, our findings suggest that alprazolam 
poses a greater risk than diazepam for subsequent aggressive behaviour, supporting prior 
discussions which have described alprazolam as one of the most problematic benzodiazepines 
(Horyniak et al., 2012; Rintoul et al., 2013), and its recent up-scheduling to a  controlled 
substance within Australia.  However, as alluded to above, consideration of alprazolam use in 
isolation of other contributing factors fails to adequately account for the processes underlying 
aggressive behaviour. Indeed, Lion and colleagues’ (1975) highlighted that it is the 
interaction between benzodiazepine use, the situation, and intrapersonal factors (and not the 
benzodiazepine alone) which influences subsequent aggressive behaviour. Given its short 
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acting effects, association with poly-substance use in the current sample, and the common 
goal to become intoxicated (25.6%), alprazolam-related aggression may indeed reflect the 
context of use, to a greater extent than the physiological effects of alprazolam. However, 
further research using urinalysis and an in-depth analysis of substance use patterns is 
required.  
Interestingly, general aggression was significantly negatively predicted by diazepam 
use. Within the current sample, diazepam was used more for alleviation of negative 
emotional and physical states (i.e., anxiety, tension, or effects of withdrawal; 41.1%), rather 
than to get high (14.5%), whereas alprazolam use is more evenly attributed to both reasons.  
This differentiation further highlights the role that approach motivations (rather than 
avoidance motivational tendencies) may have in the experience of benzodiazepine-related 
aggression. Furthermore, unlike alprazolam, diazepam appears to be infrequently used within 
the context of poly-substance use, and therefore may be generally used in scenarios with less 
risk of aggressive interactions. In addition, only when diazepam-preferring participants were 
examined in isolation, of whom predominantly displayed a moderate or high risk of 
dependence (i.e., difficulty managing diazepam use, experience of problematic diazepam-
related outcomes), did we find a positive association with aggressive outcomes. 
Comparatively, the regression analyses were conducted with all participants who had 
reported historically using diazepam for NMP reasons (i.e., not necessarily frequent, ongoing, 
dependent use). Therefore, it could be concluded that diazepam poses a risk for 
benzodiazepine-related aggression only in those who display increasingly problematic 
patterns of diazepam use, rather than to the majority who use diazepam on a less regular 
basis. This has important implications for the continued prescription of diazepam, 
highlighting the importance of prescribers carefully monitoring patient adherence to low 
dose, short term use, and the potential benefits of prioritising non-medicinal approaches when 
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assisting patients (Dobbin, 2014; Lader, 2014). Comparatively, alprazolam appears to be a 
risk for aggression at both dependent (problematic) levels and for those with less frequent 
use, and may be best prescribed only after exhausting other treatment options.  
4.3 Limitations and strengths  
A number of limitations must be acknowledged. Due to the cross-sectional nature of 
the study, causality cannot be implied, and data collection relied on uncorroborated, 
retrospective self-report which may be vulnerable to attributional and self-presentational 
biases and memory decay. The likelihood of selection bias impacting the sample is also taken 
into account, as is the absence of a non-benzodiazepine using control group. In addition, the 
findings are limited in generality, and cannot be reliably applied to individuals who commit 
more severe violence. Moreover, it cannot be discounted that other substances used in 
combination with benzodiazepines may have impacted the findings (Sweeney and Payne, 
2012). Furthermore, the current study did not permit direct examination of frustrative non-
reward or neural activity, as this can only be examined when reward pathways are activated.  
Despite these caveats, the current study has a number of important and unique 
strengths. First, specific benzodiazepines are explored, allowing greater specificity than the 
majority of cross-sectional studies available. Second, the sample is relatively large, with an 
almost even gender split; the latter feature absent in a number of well-designed, though male-
only, examinations of benzodiazepine-related aggression (see Albrecht et al., 2014 for a 
review). Third, the response is explored through the application of a clear theoretical 
framework. 
5.0 Conclusion 
Intrapersonal factors are important in understanding benzodiazepine-related 
aggression (Lion et al., 1975; Hoaken and Stewart, 2003). Notably, individuals exhibiting 
high BAS-Dr may be more vulnerable to engaging in aggression post-benzodiazepine use. In 
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addition, general diazepam use (i.e., not in the context of dependency) appears to reduce the 
risk of general aggressive behaviour (i.e., anger, hostility, verbal aggression), whilst 
alprazolam increases the risk of aggression, regardless of dose. The findings highlight the 
benefit of attending to approach and avoidance motivations, as well as frustration tolerance 
and impulse control, within offender rehabilitation programs and when prescribing 
benzodiazepines. Importantly, this study supports current guidelines which emphasise 
exploring (and exhausting) non-medicinal options before prescribing benzodiazepines, and 
the rescheduling of alprazolam to a controlled substance. 
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Tables 
 
Table 1. Participant demographic characteristics. 
Characteristic 
Total 
N % 
Male 128 62.7 
Female 76 37.3 
Country of Origin   
Australia 74 36.3 
New Zealand 5 2.5 
Asia 6 2.9 
Europe 13 6.4 
USA/Canada 96 47.1 
United Kingdom 8 3.9 
Other 2 1.0 
Student   
Yes 89 43.6 
No 112 54.9 
Education   
Before year 12 31 15.2 
Year 12 79 38.7 
University/TAFE 94 46.1 
Employed   
No 100 49.0 
Yes 100 49.0 
Treatment Ever Current 
Drug 86 (42.2) 42 (20.6) 
Alcohol 31 (15.2) 23 (11.3) 
Mental Health 140 (68.6) 83 (40.7) 
Criminal History Ever charged Ever convict 
AOD 66 (32.4) 39 (19.1) 
Violence 16 (7.8) 10 (4.9) 
Substance Use Lifetime Month prior 
Tobacco 183 (89.7) 124 (60.8) 
Alcohol 194 (95.1) 156 (76.5) 
Cannabis 189 (92.6) 121 (59.3) 
Cocaine 122 (59.8) 27 (13.2) 
Amphetamines 168 (82.4) 76 (37.3) 
Inhalants 67 (32.8) 15 (7.4) 
Hallucinogens 143 (70.1) 41 (20.1) 
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Opioids 148 (72.5) 85 (41.7) 
Note. Unless where specified, sample percentages are enclosed in brackets. Substance use frequencies reflect 
any use (illicit or prescribed). 
Note. AOD = Alcohol and other drugs; convict = convicted. 
 
Table 2. Standardised questionnaire score ranges, means and standard deviations. 
Tool 
Total 
Range M (n) SD (%) 
ASSIST    
SSI diazepam (n = 45) 2-36 12.76 10.20 
Low risk 0-3 (9) (20.0) 
Moderate risk 4-26 (30) (66.7) 
High risk 27+ (6) (13.3) 
SSI alprazolam (n = 77) 0-39 15.74 11.22 
Low risk 0-3 (8) (10.4) 
Moderate risk 4-26 (52) (67.5) 
High risk 27+ (17) (22.1) 
DASS-21    
Depression 0-21 10.12 6.44 
Anxiety 0-21 7.78 5.57 
Stress 0-21 10.01 5.38 
BIS/BAS    
BAS-Dr 5-16 10.66 2.47 
BAS-FS 6-16 12.11 2.37 
BAS-RR 11-20 15.99 2.11 
BIS-Anx 6-16 13.09 2.41 
BIS-Fear 4-12 9.21 2.08 
AQ    
Total score 29-137 69.99 23.90 
Physical 9-43 19.06 7.91 
Note. ASSIST = Alcohol, Smoking and Substance Involvement Screening Test (WHO, 2002); AQ = Aggression 
Questionnaire (Buss & Perry, 1992); BIS/BAS = Behavioural Inhibition System and Behavioural Activation 
System Scales (Carver & White, 1994); BAS-Dr = Drive, BAS-RR = Reward Responsiveness; BAS-FS =Fun 
Seeking; BIS-Anx = Anxiety; DASS-21 = Depression, Anxiety, and Stress Scales (Lovibond & Lovibond, 
1995); SSI = Specific Substance Involvement score. 
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Table 3. Lifetime NMP use per benzodiazepines, frequency of alprazolam and diazepam use in past year . 
Benzodiazepine 
Ever NMP  Frequency of use 
n (%)  Alprazolama Diazepama 
Alprazolam 157 (54.3) Never 33 (20.2) 36 (22.0) 
Temazepam 61 (21.2) Once or twice 49 (30.1) 61 (37.2) 
Oxazepam  39 (13.5) Monthly 30 (18.4) 28 (17.1) 
Lorazepam  71 (24.6) Weekly 32 (19.6) 14 (8.5) 
Diazepam 153 (52.9) Daily 19 (11.7) 25 (15.2) 
Clonazepam  70 (24.2)    
Flunitrazepam  27 (9.3)    
a Percentages reflect those reporting ever using selected benzodiazepine for NMP reasons. 
 
Table 4. Typical and maximum alprazolam and diazepam doses used per day, with approximate diazepam 
equivalent doses (DZM). 
Benzodiazepine 
Typical  Maximum 
n Range 
M 
(SD) 
Approximate 
DZMa (mgs) 
 
n Range 
M 
(SD) 
Approximate 
DZM (mgs) 
Alprazolam 119 0-15.0 
3.88 
(4.29) 
38.8 
 
118 0-33.0 
8.12 
(8.71) 
81.2 
Diazepam 111 0-61.0 
16.96 
(15.71) 
16.96 
 
110 1-161.0 
39.81 
(41.97) 
39.81 
Note. Approximate DZM = approximate diazepam equivalent dose; mgs = milligrams. 
a
 Approximate DZM computed using a 1:10 ratio for alprazolam, as suggested by dosing conversion table 
outlined by Farinde (2014). 
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Table 6. Hierarchical multiple regression predicting benzodiazepine-related general aggression. 
 B S.E Beta t p 
95% C.I. for B Part 
correlation 
coefficient 
Lower Upper 
Constant 91.56 20.09  4.558 0.000 51.93 131.19  
Recruitment 8.96 4.10 0.15 1.793 0.075 -0.90 18.82 0.120 
Age -0.06 0.20 -0.03 -0.316 0.752 -0.45 0.33 -0.021 
Gender -1.13 3.42 -0.02 -0.331 0.741 -7.88 5.62 -0.022 
Viol Conv 10.09 7.82 0.10 1.290 0.199 -5.34 25.52 0.086 
Reg Dr -2.42 4.71 -0.04 -0.513 0.609 -11.70 6.87 -0.034 
Reg Alc 2.12 3.89 0.05 0.545 0.586 -5.55 9.80 0.036 
Alprazolam 11.70 3.88 0.25 3.012 0.003 4.04 19.36 0.201 
Diazepam -8.83 3.73 -0.19 -2.366 0.019 -16.19 -1.47 -0.158 
BAS-FS -0.166 0.87 -0.17 -1.905 0.058 -3.38 0.06 -0.127 
BAS-RR -0.76 0.90 -0.07 -0.849 0.397 -2.53 1.01 -0.057 
BAS-Dr^ 2.86 0.83 0.30 3.451 0.001 1.23 4.50 0.230 
BIS-Anx^ 0.10 0.83 0.01 0.124 0.901 -1.54 1.74 0.008 
BIS-Fear 1.03 0.98 0.09 1.056 0.293 -0.90 2.97 0.070 
AnxXDr ^ 0.35 0.26 0.09 1.330 0.185 -0.17 0.86 0.089 
Note. Viol Conv = violent conviction; Reg Drg = regular drug use (previous 3 months); Reg Alc = regular 
alcohol use (previous 3 months); BAS-Dr = drive subscale, BAS-RR = reward responsiveness subscale; BAS-
FS = fun seeking subscale; BIS-Anx = anxiety subscale; BIS-Fear = fear subscale; AnxXDr = interaction term. 
^ centered variables. 
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Table 7. Hierarchical multiple regression predicting benzodiazepine-related physical aggression. 
 B S.E Beta t p 
95% C.I. of B Part 
correlation 
coefficient 
Lower Upper 
Constant 29.51 6.79  4.349 0.000 16.12 42.89  
Recruitment 3.15 1.69 0.16 1.867 0.063 -0.18 6.48 0.127 
Age -0.02 0.07 -0.03 -0.319 0.750 -0.15 0.11 -0.022 
Gender -0.46 1.16 -0.03 -0.397 0.692 -2.74 1.82 -0.027 
Viol Conv 3.79 2.64 0.11 1.434 0.153 -1.42 9.00 0.098 
Reg Drg -0.06 1.59 -0.00 -0.037 0.971 -3.20 3.08 -0.003 
Reg Alc 0.86 1.31 0.06 0.654 0.514 -1.73 3.45 0.044 
Alprazolam 2.63 1.31 0.17 2.004 0.046 0.04 5.22 0.136 
Diazepam -1.95 1.26 -0.12 -1.546 0.124 -4.44 0.54 -0.105 
BAS-FS -0.58 0.29 -0.18 -1.96 0.052 -1.16 0.01 -0.133 
BAS-RR -0.19 0.30 -0.05 -0.613 0.541 -0.78 0.41 -0.042 
BAS-Dr^ 0.88 0.28 0.28 3.154 0.002 0.33 1.44 0.215 
BIS-Anx^ -0.12 0.28 -0.03 -0.419 0.676 -0.67 0.44 -0.028 
BIS-Fear -0.16 0.33 -0.04 -0.47 0.639 -0.81 0.50 -0.032 
AnxXDr ^ 0.00 0.09 0.00 0.011 0.991 -0.17 0.17 0.001 
Note. Viol Conv = violent conviction; Reg Drg = regular drug use (previous 3 months); Reg Alc = regular 
alcohol use (previous 3 months); BAS-Dr = drive subscale, BAS-RR = reward responsiveness subscale; BAS-
FS = fun seeking subscale; BIS-Anx = anxiety subscale; BIS-Fear = fear subscale; AnxXDr = interaction term. 
^ centered variables. 
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Table 5. Bivariate correlations between factors of interest. 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 
1. Age -                     
2. 
Gender 
0.21
** 
                    
3. Alp 
dose 
typical 
0.25
** 
0.0
1                    
4. Alp 
dose 
maximu
m 
0.13 
-
0.0
4 
0.91
** 
                  
5. Dz 
dose 
typical 
0.02 
-
0.0
7 
0.35
** 
0.40
** 
                 
6. Dz 
dose 
maximu
m 
-0.04 
-
0.0
7 
0.29
* 
0.37
** 
0.83 
** 
                
7. DASS 
Dep 0.08 
0.0
1 0.08 0.10 0.08 0.05                
8. DASS 
Anx 0.04 
0.0
9 -0.12 -0.13 0.16 0.09 
0.58
** 
              
9. DASS 
Str 0.11 
0.1
1 -0.03 -0.05 0.15 0.09 
0.66
** 
0.80
** 
             
10. BAS 
DR 0.06 
0.0
5 0.08 0.11 0.12 0.11 0.03 
0.24
** 
0.23
** 
            
11. BAS 
FS 0.00 
-
0.0
6 
0.08 0.18 0.04 0.11 0.08 0.07 0.03 0.48
** 
           
12. BAS 
RR 0.00 
0.0
7 0.05 0.07 0.03 -0.02 
-
0.16
* 
0.00 0.03 0.40
** 
0.38
** 
          
DRIVE, ALPRAZOLAM & AGGRESSION  33 
 
13. BIS 
Anx 0.04 
0.1
3 
-
0.25
** 
-
0.28
** 
-0.06 -0.14 0.24
** 
0.29
** 
0.36
** 
-
0.17
** 
-
0.19
* 
0.11          
14. BIS 
Fear -0.01 
0.0
8 
-
0.21
* 
-
0.25
** 
0.05 -0.12 0.30
** 
0.30
** 
0.36
** 
-
0.24
** 
-
0.32
** 
-
0.00 
0.54
** 
        
15. AQ 
Total 0.04 
-
0.0
3 
0.09 0.08 0.14 0.17 0.33
** 
0.33
** 
0.46
** 
0.21
** 
-0.01 0.05 0.08 0.08        
16. AQ 
Phys 0.04 
-
0.0
6 
0.10 0.10 0.14 0.16 0.22
** 
0.22
** 
0.34
** 
0.22
** 
0.03 0.05 -0.04 -0.07 0.87
** 
      
17. Viol 
Conv 0.10 
-
0.0
3 
0.07 0.14 0.16 0.40
** 
0.04 0.12 0.15
* 
0.28
** 
0.18
** 
0.08 -0.05 
-
0.23
** 
0.17
* 
0.21
** 
     
18. AOD 
Conv 
0.25
** 
-
0.0
6 
0.24
** 
0.28
** 
0.19 0.30
** 
0.05 0.11 0.04 0.13 0.14
* 
0.04 -0.11 
-
0.15
* 
0.05 0.14
* 
0.35
** 
    
19. Poly 
BZD -0.04 
-
0.0
7 
0.25
** 
0.25
** 
0.15 0.03 0.10 0.15
* 
0.14
* 
0.22
** 
0.25
** 
0.14
* 
-0.02 -0.05 0.13 0.12 0.14
* 
0.05    
20. 
ASSIST 
Alp 
0.24
* 
-
0.1
7 
0.38
** 
0.41
** 
0.50
** 
0.50
** 
0.27
* 
0.17 0.31
** 
0.16 0.04 -0.01 0.02 -0.12 
0.33
** 
0.28
* 
0.21 0.30
** 
0.24
* 
  
21.ASSI
ST Dz 
0.33
* 
0.2
8 -0.18 -0.22 
0.39
* 
0.46
** 
0.30
* 
0.43
** 
0.54
** 
0.28 -0.05 0.05 0.25 0.07 0.53
** 
0.48
** 
0.26 0.13 0.11 a  
22. Reg 
Sub -0.07 
-
0.0
2 
0.18 0.13 0.02 -0.06 0.15 0.05 0.10 0.12 0.21
** 
0.02 -0.15 -0.10 0.14 0.14 0.03 0.13 0.22
** 
0.2
3 
-
0.1
4 
Note. Alp = alprazolam; Dz = diazepam; DASS Dep = DASS Depression scale; DASS Anx = DASS Anxiety scale; DASS Str = DASS Stress scale; BAS Dr = Drive scale; 
BAS FS = Fun Seeking scale; BAS RR = Reward Responsiveness scale; BIS Anx = Anxiety scale; BIS Fear = Fear scale; AQ = Aggression Questionnaire; AQ Phys = 
Aggression Questionnaire Physical subscale; Viol Conv = violent conviction; AOD Conv = drug or alcohol related conviction; Poly BZD = use of other substances when 
taking non-medically prescribed benzodiazepines; ASSIST Alp = total ASSIST score for those who prefer alprazolam; ASSIST Dz = total ASSIST score for those who prefer 
diazepam; Reg Sub = number of substances regularly (at least weekly) used.  
a
 correlation unable to be computed as discrete subsamples based on preferential benzodiazepine used for non-medically prescribed reasons. 
* p < 0.01 
** p < 0.001 
